Luiz Tófoli
Professor in the Department of Psychiatry, Faculty of Medical Sciences, UNICAMP
Data updated
Research Footprint
Luiz Tófoli appears in 24 tracked papers (2015–2023), most studied alongside Ayahuasca, LSD and Ibogaine, across Substance Use Disorders (SUD), Depressive Disorders and Anxiety Disorders.
Most-cited paper: Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial (814 citations).
Frequent co-authors: Draulio Araújo, Sidarta Ribeiro and Fernanda Palhano-Fontes.
Publication Landscape
How the 24 papers Blossom tracks for Luiz Tófoli line up by year, topic, and journal. These are the psychedelic-relevant papers in Blossom's records as of July 2026, not a complete bibliography.
How has Luiz Tófoli's publishing grown?
SourcedTracked papers by publication year. Click a year for the running total.
Don't read as total output: only the 24 of 24 tracked papers with a recorded publication date are counted, and these are the psychedelic-relevant papers Blossom tracks, not a complete bibliography. The current year is still filling in.
What does Luiz Tófoli publish on?
SourcedTracked papers per topic. Orange marks the largest research focus.
Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Where does Luiz Tófoli publish?
SourcedTracked papers per journal. Orange marks the most-used journal.
Counts the journal recorded on each tracked paper; preprints and papers with no journal on file are not shown. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Background & Research
Luiz F. Tófoli is a Brazil-based clinical researcher whose work bridges empirical, qualitative and psychometric approaches within contemporary psychedelic science. Tófoli has contributed to large-scale survey research (including analyses from the Global Ayahuasca Survey) that characterises adverse events, use patterns and wellbeing outcomes among ayahuasca users, and has led or co-authored studies examining subjective experiential reports through quantitative textual and phenomenological methods. He has also investigated the influence of context and setting on ayahuasca outcomes and contributed to the development and review of psychometric instruments for psychedelic research.
In addition to naturalistic and survey work, Tófoli has been involved in clinical and treatment-focused research, including an open-label pilot of MDMA-assisted psychotherapy for victims of sexual abuse with severe PTSD and phenomenological analyses of ibogaine in the context of drug-dependence treatment. His publications emphasise safety profiles, subjective experience, and methodological rigour for studying both therapeutic potential and risks of classic and non-classic psychedelics, with recurrent focus on depressive disorders, PTSD and substance-use disorders.
Key Impact
Notable for empirical and methodological contributions to the study of ayahuasca, ibogaine and early-stage psychedelic-assisted therapies in Brazil, including survey research on adverse effects and pilot clinical work with MDMA-assisted psychotherapy.
Collaboration Network
42 collaborators· click a node to visit their profile
Full network →Collaboration Network
See Luiz Tófoli's full collaboration network, shared papers, and research connections.
Compounds
Topics
Top Collaborators
Top Collaborators
Unlock clinical summaries, full texts, and related trial mapping.
Affiliations
Institutions, companies, and organisations Luiz Tófoli is associated with.